Chondroblastoma of extra‐craniofacial bones: Clinicopathological analyses of 103 cases

Konishi, Eiichi; Nakashima, Yasuaki; Mano, Masayuki; Tomita, Yoshihiro; Kubo, Toshikazu; Araki, Nobuhito; Morii, Eiichi; Yoshikawa, Hideki; Haga, Hironori; Toguchida, Junya; Ueda, Takafumi; Osawa, Motoki; Hoshi, Manabu; Inoue, Takeshi; Aono, Masanari; Yanagisawa, Akio

doi:10.1111/pin.12586

Cited by 32 publications

(40 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It usually affects the epiphyses or apophyses of long bones such as humerus, femur and tibia. Less common location affected by chondroblastoma including patella, calcaneus, acetabulum and even spine, also had been reported in literature [9][10][11].It seems that chondroblastoma occurs more frequently in males than in females, in a ratio of 2.3 to 1 [2,12]. In this group of patients, the mean age of onset was 13 years old with a male to female ratio of 1.5:1, and also the proximal humerus was the mostly involved location, which all coincided with most previous studies.…”

Section: Discussionmentioning

confidence: 73%

10 Years Follow up of Chondroblastoma Treated with Intralesional Curettage: A Retrospective Study

Yang

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Introduction: Chondroblastoma is a rare benign tumor mainly occurred in epiphyses and apophyses of long bones, and usually affects the young people. The primary treatment for chondroblastoma is intralesional curettage. The aim of this study was to evaluate the clinical and radiologic results of patients suffering chondroblastoma treated with intralesional curettage, electrocauterization of the cavity and bone grafting. Patients and Methods: From January 2000 to January 2010, 15 patients with chondroblastoma were treated with intralesional curettage and electrocauterization of the cavity, among which14 patients received bone grafting. After operation, patients were immobilized with splint for 4 weeks and followed up for at least 10 years. The recurrence was examined by clinical manifestation and X ray. The clinical outcome included complications and the Musculoskeletal Tumor Society Score (MSTS).Results: Totally, 15 patients with chondroblastoma were enrolled in our study, including 9 males and 6 females, with a mean age of 13 years old (range from 8 to 21 years). The most common chief compliant were pain and limited joint motion, others including local swelling and increased skin temperature. The mean duration of symptom was 5 months (range from 2-14 months). Tumors mostly affected the proximal humerus (7/15), distal femur (4/15), proximal femur (1/15), proximal tibia (2/15) and femoral head (1/15). Eight patients were undiagnosed or misdiagnosed before operation, only 7 patients with a consideration of chondroblastoma. With a mean follow up of 12years (range from 10-16 years) , two patients had complications of upper limb shortening and1 patient suffered re-operation due to tumor recurrence. The mean postoperative MSTS score was 28.1 (range, 24 to 30) points, which was significantly higher than the preoperative score of 17.6 (range, 12 to 21) points.Conclusion: Thorough curettage with electrocauterization and bone grafting has a good functional outcome in the treatment of chondroblastoma, but still has a low risk of recurrence and complications.Level of Evidence: Level IV, retrospective case series.

show abstract

Section: Discussionmentioning

confidence: 73%

10 Years Follow up of Chondroblastoma Treated with Intralesional Curettage: A Retrospective Study

Yang

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…It mostly affects the epiphyses or apophyses of long bones such as humerus, femur and tibia. Less common locations including patella, calcaneus, acetabulum and spine, also had been reported in literature [9][10][11].It seems that chondroblastoma occurs more frequently in males than in females, with a ratio of 2.3 to 1 in literature [2,12]. In our study of chondroblastoma , the mean age of onset was 13 years old with a male to female ratio of 1.5:1, and also the proximal humerus was the mostly involved location, which all coincided with most previous studies.…”

Section: Discussionmentioning

confidence: 83%

Outcome of Chondroblastoma Treated With Intralesional Curettage and Autogenous Iliac Bone Graft: A Retrospective Study

Yang¹,

Yang²,

Wang³

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundChondroblastoma is a rare benign tumor mainly occurred in epiphyses and apophyses of long bones, and usually affects the young people. The primary treatment for chondroblastoma is intralesional curettage. The aim of this study was to evaluate the clinical result of patients suffering chondroblastoma treated with intralesional curettage, electrocauterization of the cavity and autogenous iliac bone grafting. MethodsFrom January 2000 to January 2010, 15 patients with chondroblastoma were treated with intralesional curettage and electrocauterization of the cavity, and 14 of them received autogenous iliac bone grafting. After operation, patients were immobilized with splint for 4 weeks and followed up for at least 10 years. The recurrence was examined by clinical manifestation and X ray. The clinical outcome included complications and the Musculoskeletal Tumor Society Score (MSTS).ResultsTotally, 15 patients with chondroblastoma were enrolled in our study, including 9 males and 6 females, with a mean age of 13 years old (range from 8 to 21 years). The most common chief compliant were pain and limited joint motion, others including local swelling and increased skin temperature. The mean duration of symptom was 5 months (range from 2-14 months). Tumors mostly affected the proximal humerus (7/15), distal femur (4/15), proximal femur (1/15), proximal tibia (2/15) and femoral head (1/15). With a mean follow up of 12years (range from 10-16 years) , two patients had complications of upper limb shortening and one patient suffered re-operation due to tumor recurrence. The mean postoperative MSTS was 28.1 (range, 24 to 30) points, which was significantly higher than the preoperative score of 17.6 (range, 12 to 21) points.ConclusionsThorough curettage with electrocauterization and autogenous iliac bone grafting has good functional outcomes in the treatment of chondroblastoma, but still has a low risk of recurrence and complications.Level of EvidenceLevel IV, retrospective case series.

show abstract

“…Considering that CB is essentially a benign bone tumor that rarely metastasizes [2,3,8,15], intralesional curettage [19]. While a component of aneurysmal bone cysts has been considered to be associated with aggressive CB [20], other studies have failed to confirm this [2,15,21].…”

Section: Discussionmentioning

confidence: 99%

“…Similarly, Sailhan et al observed that epiphyseal- metaphyseal CB was not associated with a higher recurrence rate compared to epiphyseal CB [1]. Furthermore, no studies have succeeded to identify predictive pathological features for aggressive CB [19,21]. Typically, autogenous or allogeneic bone graft or polymethylmethacrylate has been used to fill the bone defect after curettage of benign bone tumor.…”

Section: Discussionmentioning

confidence: 99%

Clinical outcomes of chondroblastoma treated using synthetic bone substitute: risk factors for developing radiographic joint degeneration

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Chondroblastoma (CB) is a rare locally aggressive bone tumor that commonly occurs in the epiphysis or apophysis of long bones. Although surgical treatment of CB carries potential risk for physeal or articular cartilage damage, risk factors for joint degeneration have not been well described. In addition, we have mainly used synthetic bone substitute (SBS) to fill the bone defect after intralesional curettage as treatment for CB. This study thus aimed to evaluate the incidence of and risk factors for adjacent-joint radiographic degeneration after SBS treatment for CB. Methods: We retrospectively reviewed 48 patients treated for CB at our institutions between 1996 and 2017. Clinical data, radiographic images, treatments, and local recurrence were analyzed. Results: We identified 40 patients [29 males and 11 females with a mean age of 19 years (range, 8-35 years)] who received SBS to fill the defect after curettage with a minimum follow-up of 1 year. The mean follow-up period was 71 months (range, 13-239 months). A total of 8 patients (20%) developed local recurrence. Radiographic analysis showed that 5 patients (16.7%) developed radiographic joint degeneration. Joint degeneration was significantly associated with the affected joint (p = 0.004). Conclusions: Curettage and SBS filling had been found to be a reasonable treatment method for CB, which commonly occurs in the epiphysis or apophysis. Radiographic joint degeneration was not uncommon after CB treatment, especially in the talus and proximal humerus.

show abstract

Chondroblastoma of extra‐craniofacial bones: Clinicopathological analyses of 103 cases

Cited by 32 publications

References 13 publications

10 Years Follow up of Chondroblastoma Treated with Intralesional Curettage: A Retrospective Study

10 Years Follow up of Chondroblastoma Treated with Intralesional Curettage: A Retrospective Study

Outcome of Chondroblastoma Treated With Intralesional Curettage and Autogenous Iliac Bone Graft: A Retrospective Study

Clinical outcomes of chondroblastoma treated using synthetic bone substitute: risk factors for developing radiographic joint degeneration

Contact Info

Product

Resources

About